Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

被引：86

作者：

Yang, Yunpeng ^{[1
]}

Pan, Jianji ^{[2
]}

Wang, Hui ^{[3
]}

Zhao, Yuanyuan ^{[1
]}

Qu, Shenhong ^{[4
]}

Chen, Nianyong ^{[5
,6
]}

Chen, Xiaozhong ^{[7
]}

Sun, Yan ^{[8
]}

He, Xiaohui ^{[9
]}

Hu, Chaosu ^{[10
]}

Lin, Lizhu ^{[11
]}

Yu, Qitao ^{[12
]}

Wang, Siyang ^{[13
]}

Wang, Guihua ^{[14
]}

Lei, Feng ^{[15
]}

Wen, Jiyu ^{[16
]}

Yang, Kunyu ^{[17
]}

Lin, Zhixiong ^{[18
]}

Guo, Ye ^{[19
]}

Chen, Shaoqing ^{[20
]}

Huang, Xiaoming ^{[21
]}

Wu, Yanjie ^{[22
]}

Liang, Liang ^{[23
]}

Chen, Chenqi ^{[22
]}

Bai, Fan ^{[22
]}

Ma, Xiaopeng ^{[24
]}

Zhang, Yun ^{[23
]}

Leaw, Shiangjiin ^{[22
]}

Zhang, Li ^{[1
]}

Fang, Wenfeng ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Med Oncol Sun Yat, State Key Lab Oncol South China,Canc Ctr,Guangdong, 16th Floor,2 Bldg,Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China

[2] Fujian Canc Hosp, Dept Head & Neck Radiat Oncol, 420 Fuma Rd, Fuzhou 350014, Fujian, Peoples R China

[3] Hunan Canc Hosp, Thorac Radiotherapy Dept 1, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China

[4] Guangxi Acad Med Sci, Peoples Hosp Guangxi Zhuang Autonomous Reg, Canc Res Inst, Otolaryngol Dept, 6 Tao Yuan Rd, Nanning 530021, Guangxi, Peoples R China

[5] Sichuan Univ, West China Hosp, Canc Ctr, Dept Head & Neck Oncol, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China

[6] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China

[7] Zhejiang Canc Hosp, Dept Head & Neck Radiotherapy, 38 Guangji Rd, Hangzhou 310022, Zhejiang, Peoples R China

[8] Beijing Canc Hosp, Radiotherapy Dept, 52 Fucheng Rd, Beijing 100142, Peoples R China

[9] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, 17 Panjiayuannanli, Beijing 100021, Peoples R China

[10] Fudan Univ, Shanghai Canc Ctr, Dept Radiat, 270 Dongan Rd, Shanghai 200032, Peoples R China

[11] Guangzhou Tradit Chinese Med Univ, Affiliated Hosp 1, Dept Oncol, 16 Airport Rd, Guangzhou 510405, Guangdong, Peoples R China

[12] Guangxi Med Univ, Affiliated Canc Hosp, Dept Med Oncol Resp, 71 Hedi Rd, Nanning 530021, Guangxi, Peoples R China

[13] Sun Yat Sen Univ, Affiliated Hosp 5, Head & Neck Oncol Sect 1, 52 Meihua East Rd, Zhuhai 519000, Peoples R China

[14] Changsha Cent Hosp, Dept Oncol, 161 Shaoshan South Rd, Changsha 410004, Hunan, Peoples R China

[15] Peoples Hosp Zhongshan City, Head & Neck Radiotherapy Dept, 2 Sunwen East Rd, Zhongshan 528403, Guangdong, Peoples R China

[16] Guangdong Med Univ, Affiliated Hosp, Canc Ctr, Nasopharyngeal Canc Dis Ctr, 57 South Renmin Rd, Zhanjiang 524000, Guangdong, Peoples R China

[17] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China

[18] Shantou Univ, Canc Hosp, Med Coll, Dept Radiat, 7 Raoping Rd, Shantou 515031, Guangdong, Peoples R China

[19] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, 1800 Yuntai Rd, Shanghai 200123, Peoples R China

[20] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, 17 Yongwaizheng St, Nanchang 330006, Jiangxi, Peoples R China

[21] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Otolaryngol Head & Neck Surg, 107 Yan Jiang West Rd, Guangzhou 510120, Guangdong, Peoples R China

[22] BeiGene Shanghai Co Ltd, Jing Kerry Ctr, Clin Dev, 20-F,Tower 3,1228 Middle Yanan Rd, Shanghai 200040, Peoples R China

[23] BeiGene Beijing Co Ltd, Clin Biomarker Sci & CDx Dev, 6 Jianguomenwai Ave,SK Tower,36th Floor, Beijing 100022, Peoples R China

[24] BeiGene Beijing Co Ltd, Bioinformat, 30 Sci Pk Rd,Zhongguancun Life Sci Pk, Beijing 102206, Peoples R China

来源：

CANCER CELL | 2023年 / 41卷 / 06期

关键词：

biomarker; clinical trial; double-blinded; gene expression profiling; immunotherapy; nasopharyngeal carcinoma; PD-1; inhibitor; randomized; tislelizumab;

D O I：

10.1016/j.ccell.2023.04.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4-6 cycles). At interim analysis, progression-free survival (PFS) was significantly longer with tislelizumab-chemotherapy versus placebo -chemotherapy (hazard ratio: 0.52; 95% confidence interval: 0.38, 0.73; p < 0.0001). PFS benefit for tislelizumabchemotherapy versus placebo-chemotherapy was observed regardless of programmed death-ligand 1 expression. PFS after next line of treatment and overall survival showed favorable trends for tislelizumab-chemotherapy versus placebo-chemotherapy. The safety profile was similar between arms. Gene expression profiling (GEP) identified immunologically "hot"tumors, and showed an activated dendritic cell (DC) signature was associated with tislelizumab-chemotherapy PFS benefit. Our results support that tislelizumab-chemotherapy should be considered as first-line treatment for R/M NPC, and GEP and activated DC signature results may help identify patients who might benefit most from immunochemotherapy treatment.

引用

页码：1061 / +

页数：17

共 50 条

[31] Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
Wang, J.
Lu, S.
Yu, X.
Hu, Y.
Zhao, J.
Sun, M.
Yu, Y.
Hu, C.
Yang, K.
Song, Y.
Lin, X.
Liang, L.
Leaw, S.
Zheng, W.
ESMO OPEN, 2024, 9 (10)
[32] Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study
Xiang Ren
Yiqun Tian
Zhixian Wang
Jing Wang
Xing Li
Yisheng Yin
Ruibao Chen
Ying Zhan
Xiaoyong Zeng
BMC Urology, 22
[33] DOCETAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER
Ohhara, Y.
Nishimura, N.
Nara, E.
Nakano, K.
Ueda, K.
Sakajiri, S.
Mishima, Y.
Yokoyama, M.
Terui, Y.
Takahashi, S.
Hatake, K.
ANNALS OF ONCOLOGY, 2012, 23 : 125 - 125
[34] Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
Shen, B.
Pan, B.
Wu, Y.
Shi, L.
Gao, J.
Feng, J.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S379 - S379
[35] Multicenter phase II trial of S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable colorectal cancer
Shin, S.
Park, Y.
Kim, T.
Oh, D.
Shim, B.
Lee, K.
Lee, M.
Kim, Y.
Kim, Y.
Ahn, J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[36] RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma
Xu, R.
Arkenau, T.
Bang, Y.
Denlinger, C.
Kato, K.
Tabernero, J.
Wang, J.
Li, J.
Castro, H.
Moehler, M.
ANNALS OF ONCOLOGY, 2020, 31 : S97 - S98
[37] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
Bai, Long
Wang, Feng
Li, Zhe-zhen
Ren, Chao
Zhang, Dong-sheng
Zhao, Qi
Lu, Yun-xin
Wang, De-shen
Ju, Huai-qiang
Qiu, Miao-zhen
Wang, Zhi-qiang
Wang, Feng-hua
Xu, Rui-hua
MEDICINE, 2016, 95 (51) : e4531
[38] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Moehler, Markus H.
Kato, Ken
Arkenau, Hendrik-Tobias
Oh, Do-Youn
Tabernero, Josep
Cruz-Correa, Marcia
Wang, HongWei
Xu, Hui
Li, Jiang
Yang, Silu
Xu, Rui-hua
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
[39] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
Bécouarn, Y
Ychou, M
Ducreux, M
Borel, C
Bertheault-Cvitkovic, F
Seitz, JF
Nasca, S
Nguyen, TD
Paillot, B
Raoul, JL
Duffour, J
Fandi, A
Dupont-André, G
Rougier, P
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
[40] Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
Ryu, M. -H.
Baba, E.
Lee, K. H.
Park, Y. I.
Boku, N.
Hyodo, I.
Nam, B. -H.
Esaki, T.
Yoo, C.
Ryoo, B. -Y.
Song, E. -K.
Cho, S. -H.
Kang, W. K.
Yang, S. H.
Zang, D. Y.
Shin, D. B.
Park, S. R.
Shinozaki, K.
Takano, T.
Kang, Y. -K.
ANNALS OF ONCOLOGY, 2015, 26 (10) : 2097 - 2101

← 1 2 3 4 5 →